Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Mahamaya Lifesciences IPO
Price Band
₹108.0–114.0
Issue Size
₹70.44 Cr
Lot Size
1,200 shares
Min Investment
₹273,600
2 LOTS MIN
GMP
—
Issue Price
₹114.0
Mahamaya Lifesciences IPO AI Summary
- Mahamaya Lifesciences IPO is listed on BSE SME in the Pesticides & Agrochemicals sector.
- Price band: ₹108.0–₹114.0 per share, lot size 1,200 shares (min. investment ₹273,600, 2 lots minimum).
- Subscription window: 11 Nov–13 Nov 2025, listing on 18 Nov 2025.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Mahamaya Lifesciences IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 13 Nov 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Mahamaya Lifesciences IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity. The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs). The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs). The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations. Product Portfolio: Bulk Formulations Sales: Acetamiprid, SP Buprofezin, SC Emamectin benzoate, SG Imidacloprid, SC Paraquat Dichloride. Technical Sales: Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min. Branded Sales (Major own branded products): MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370 Export Sales- Formulations: Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG). Competitive Strengths: Experienced management team consisting of experts. Capability to introduce vital products for Indian Agriculture. Development of export opportunities of products. Ability to develop brands. Cordial relationships with suppliers of raw materials. Core values focused on achieving sustainability through innovative approaches.
Company Financials (₹ Cr)
As of 2025-06-30
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Total Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit After Tax | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves and Surplus | 35.73 | 31.66 | 23.41 | 18.19 |
| Total Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
Key Ratios
EPS
₹7.29
NAV
₹12.13
ROE
34.94%
ROCE
23.15%
RoNW
26.19%
P/B Value
9.40
P/E Ratio
15.65
Market Cap
₹266.82 Cr
PAT Margin
4.84%
Debt/Equity
1.08
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Bhagiradha Chemicals & Industries Ltd. | 52.61 | 2.03% | 247.63 | 1.14 | 1.14 |
| Nova Agritech Limited | 23.76 | 12.47% | 16.93 | 3.05 | 3.05 |
| Mahamaya Lifesciences Limited This IPO | 27.82 | 26.19% | — | 7.6 | 7.6 |
Promoters
Krishnamurthy Ganesan, Lalitha Krishnamurthy and Prashant Krishnamurthy
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Purchase of Equipment for existing Formulation plant 3.75 2 Funding capital expenditure towards setting up of a new technical manufacturing plant 29.42 3 Construction of Warehouse Building and Purchase of Machinery 2.53 4 Funding working capital requirements of the Company 18.00 5 General Corporate Purposes 8.26 6 Issue Expenses 2.54 Total 64.50
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹137.40 Cr in the year ended 31 Mar 2023, increasing to ₹162.83 Cr by 31 Mar 2024, and further rising to ₹267.17 Cr by 31 Mar 2025. However, the most recent figure of ₹84.04 Cr as of 30 Jun 2025 is from a 9-month period, making it not directly comparable to the full fiscal years.
Profit Trend
Profit After Tax was ₹3.75 Cr in the year ended 31 Mar 2023, increasing to ₹5.22 Cr by 31 Mar 2024, and further rising to ₹12.94 Cr by 31 Mar 2025. The most recent figure of ₹4.10 Cr as of 30 Jun 2025 is from a 9-month period, which is not directly comparable to the previous full fiscal years.
Valuation
Mahamaya Lifesciences Limited has an implied P/E of 15.65 at the issue price, compared to peers trading at P/E ratios ranging from 16.93 to 247.63.
Grey Market Premium, Explained
The Grey Market Premium (GMP) refers to the unofficial trading of shares before they are listed on the stock exchange. It can give an indication of market sentiment towards an IPO, but it is not a guaranteed predictor of listing performance.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It is important to consider the company's fundamentals and market conditions before making a decision.
Who May Want to Wait
Investors who prefer stable and predictable returns or those with a low risk tolerance may want to avoid investing in IPOs, as they can be subject to significant price fluctuations and market uncertainties.
IPO Timeline, Explained
The IPO process involves several key dates: the opening date for subscription is 11 Nov 2025, closing on 13 Nov 2025, with allotment scheduled for 14 Nov 2025 and listing on the stock exchange on 18 Nov 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit that investors can make when shares of a company are listed on the stock exchange and start trading. However, these gains are not guaranteed, and the stock price can fluctuate significantly on the listing day due to market conditions.
This evaluation is generated from Mahamaya Lifesciences's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Mahamaya Lifesciences IPO?
The price band of Mahamaya Lifesciences IPO is ₹108.0–₹114.0 per share.
When does Mahamaya Lifesciences IPO open and close?
Mahamaya Lifesciences IPO opens on 11 November 2025 and closes on 13 November 2025.
When does Mahamaya Lifesciences IPO list on the stock exchange?
Mahamaya Lifesciences IPO listed on 18 November 2025 at ₹114.0.
What is the lot size for Mahamaya Lifesciences IPO?
The lot size for Mahamaya Lifesciences IPO is 1200 shares, requiring a minimum investment of ₹273,600 (2 lots).
What is the lot size for this IPO?
The lot size for Mahamaya Lifesciences IPO is 1200 shares.
What is the minimum investment required?
The minimum investment required is ₹273,600.
What is the price band for the IPO?
The price band for the IPO is ₹108.0 to ₹114.0.
When is the listing date?
The listing date for the IPO is 18 Nov 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the price at which shares are expected to trade in the grey market before their official listing.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
11 Nov 2025
Close
13 Nov 2025
Allotment
14 Nov 2025
Listing
18 Nov 2025
Similar IPOs in Pesticides & Agrochemicals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Mahamaya Lifesciences?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.